If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibodies Regulatory News (FAB)

Share Price Information for Fusion Antibodies (FAB)

Share Price is delayed by 15 minutes
Get Live Data
12.00    0.00 (0.00%)
Bid:
11.50
Ask:
12.50
Spread: 1.00 (8.696%)
Market Cap: £15.02m
FAB Live PriceLast checked at - London Stock Exchange

Intraday Fusion Antibodies Share Chart

Net Asset Value(s)

23 Apr 2007 07:01

Fabian Romania Property Fund Ltd23 April 2007 23 April 2007 Fabian Romania Property Fund Limited ("Fabian" or the "Fund") Net Asset Value ("NAV") as at 31 March 2007 Fabian, the AIM listed property fund established to invest in Romanian property,announces that its unaudited NAV per Ordinary Share as at 31 March 2007 was€1.390. This represents an increase of +2.5 per cent. versus the €1.356 reported for 31December 2006. The NAV is calculated in accordance with the Fund's articles of association. The market valuations of the portfolio used within unaudited NAV per OrdinaryShare are: Market Value Bank (Debt)/Cash Other NAV Original InvestmentCascades office €14.7m (€9.4m) €0.3m €5.6m €12.2mBanu office €15.2m (€9.1m) €0.2m €6.3m €12.3mNew Town * €10.0m (€1.2m) €0.9m €9.7m €5.75mLakeview * €8.3m (€5.1m) - €3.2m €5.3mBank Cash - €46.4m - €46.4mOther - - (€0.5m) (€0.5m)Sub-total €48.2m €21.6m €0.9m €70.7m * represents Fabian's share of the development The pipeline to invest the €40m raised on admission to AIM continues to beactively progressed in line with the stated strategy. For further information, please contact: Fabian Romania Property Fund LimitedMark Holdsworth 020 7499 9988 Shore Capital Stockbrokers LimitedDru Danford 020 7408 4090 Deloitte Corporate Finance James Lewis 020 7936 3000 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
31st Mar 20255:00 pmRNSTotal Voting Rights
24th Mar 20254:38 pmRNSHolding(s) in Company
18th Mar 20257:00 amRNSPlacing to raise approximately £1.17 million
27th Feb 20257:00 amRNSContract win
31st Jan 20257:00 amRNSOptiMAL R&D Update
4th Dec 202411:31 amRNSApproval of Grant Funding Application
19th Nov 20247:00 amRNSHalf-year Report
16th Oct 20241:23 pmRNSDirector/PDMR Shareholding
16th Oct 20247:00 amRNSIssue of shares to non-executive directors
8th Oct 202412:32 pmRNSResult of AGM
8th Oct 20247:00 amRNSAGM statement and trading update
2nd Oct 20247:00 amRNSBlock admission six monthly return
12th Sep 20249:54 amRNSNotice of AGM
9th Sep 202412:35 pmRNSDirector/PDMR Shareholding
5th Sep 202412:15 pmRNSDirector/PDMR Shareholding
5th Sep 20247:00 amRNSFinal Results
22nd Jul 202412:54 pmRNSDirector/PDMR Shareholding
4th Jul 20247:00 amRNSTrading update
23rd May 20247:00 amRNSNew contract with existing client
2nd May 20247:00 amRNSInvestor presentation
30th Apr 20247:00 amRNSYear-end trading statement
16th Apr 20247:00 amRNSChange of auditor
15th Apr 20247:00 amRNSContract to develop a bespoke OptiPhage library
2nd Apr 20242:34 pmRNSBlock admission six monthly return
28th Mar 20245:00 pmRNSTotal Voting Rights
11th Mar 20243:04 pmRNSHolding(s) in Company
11th Mar 20249:10 amRNSHolding(s) in Company
8th Mar 20243:09 pmRNSHolding(s) in Company
5th Mar 202410:40 amRNSResult of General Meeting and Total Voting Rights
29th Feb 20245:00 pmRNSTotal Voting Rights
27th Feb 20247:00 amRNSFirst purchase order under MSA
14th Feb 20247:15 amRNSGrant of options and issue of shares to directors
14th Feb 20247:00 amRNSPlacing to raise £1,375,000
6th Feb 20247:00 amRNSFollow-on project award and R&D update
1st Feb 20247:00 amRNSHMRC R&D tax credit
4th Dec 202312:26 pmRNSDirector/PDMR Shareholding
4th Dec 20237:00 amRNSHalf-year Report
28th Nov 20237:00 amRNSOptiMAL collaboration agreement
9th Nov 20237:00 amRNSHalf year trading update
27th Oct 202311:57 amRNSResult of AGM
4th Oct 20232:45 pmRNSBlock admission six monthly return
29th Sep 20237:00 amRNSFinal Results
29th Aug 20237:00 amRNSUpdate on AI/ML-Ab service offering
24th Aug 20237:00 amRNSAppointment of interim CFO
21st Aug 20237:00 amRNSUpdate on AI/ML-Ab™ antibody discovery service
14th Aug 20237:00 amRNSUpdate on restructure and cost savings
30th Jun 20235:00 pmRNSTotal Voting Rights
16th Jun 202310:09 amRNSHolding(s) in Company
15th Jun 20239:45 amRNSHolding(s) in Company
13th Jun 20232:44 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.